Copyright: ©Author(s) 2026.
World J Diabetes. Nov 15, 2026; 17(11): 124628
Published online Nov 15, 2026. doi: 10.4239/wjd.124628
Published online Nov 15, 2026. doi: 10.4239/wjd.124628
Table 1 Demographic and clinical characteristics of patients with community-acquired pneumonia in this study, n (%)/median (interquartile range)
| Characteristics | CAP (n = 323) | DM-CAP (n = 87) | P value |
| Sex, male | 186 (57.59) | 57 (65.52) | 0.181 |
| Age, years | 62 (41-74) | 67 (61-78) | < 0.001 |
| Underlying disease(s) | |||
| Chronic heart diseases | 64 (19.81) | 43 (49.43) | < 0.001 |
| Hypertension | 101 (31.27) | 61 (70.11) | < 0.001 |
| Chronic renal diseases | 4 (1.24) | 5 (5.75) | 0.020 |
| Cerebrovascular diseases | 40 (12.38) | 22 (25.29) | 0.003 |
| Chronic pulmonary diseases | 22 (6.81) | 9 (10.34) | 0.899 |
| Physical examination | |||
| T max, °C | 36.80 (36.50-37.60) | 36.90 (36.50-37.50) | 0.701 |
| Respiratory frequency ≥ 30 breaths/minute | 8 (2.48) | 5 (5.75) | 0.002 |
| Heart rates ≥ 100 beats/minute | 61 (18.89) | 24 (27.59) | 0.002 |
| Confusion | 38 (11.76) | 23 (26.44) | 0.001 |
| SBP < 90 mmHg or DBP ≤ 60 mmHg | 17 (5.26) | 7 (8.05) | 0.326 |
| Laboratory results | |||
| WBC (× 109/L) | 7.75 (6.14-10.28) | 8.54 (6.51-12.62) | 0.010 |
| NEU (× 109/L) | 5.12 (3.53-7.54) | 6.40 (4.30-10.86) | 0.001 |
| LYM (× 109/L) | 1.58 (1.01-2.17) | 1.34 (0.78-1.84) | 0.013 |
| CRP (mg/L) | 19.70 (3.51-67.18) | 47.11 (12.39-117.00) | 0.001 |
| PCT (μg/L) | 0.06 (0.03-0.20) | 0.16 (0.07-0.80) | < 0.001 |
| Glu (mmol/L) | 5.02 (4.55-5.97) | 8.20 (6.11-12.17) | < 0.001 |
| ALB (g/L) | 37.37 (33.68-39.70) | 36.07 (31.32-40.07) | 0.094 |
| Cr (μmol/L) | 70.60 (58.14-83.49) | 75.47 (63.58-100.20) | 0.004 |
| BUN (mmol/L) | 4.80 (3.84-6.46) | 6.04 (4.90-9.30) | < 0.001 |
| Oncostatin M (pg/mL) | 21.25 (9.76-44.59) | 32.94 (14.54-72.34) | 0.004 |
| Interleukin-6 (pg/mL) | 4.00 (2.15-8.30) | 6.32 (3.38-15.21) | < 0.001 |
| Interleukin-8 (pg/mL) | 15.25 (11.19-22.02) | 17.51 (12.76-31.09) | 0.023 |
| Chest CT | |||
| Multipolar infiltrates | 168 (52.01) | 54 (62.07) | 0.095 |
| Pleural effusion | 53 (16.41) | 19 (21.84) | 0.237 |
| Treatment | |||
| Intravenous hormone therapy | 42 (13.00) | 11 (12.64) | 0.929 |
| Vasoactive drug therapy | 15 (4.64) | 14 (16.09) | < 0.001 |
| CURB-65 score | 0 (0-1) | 1 (0-2) | < 0.001 |
| PSI score | 61 (40-90) | 85 (65-119) | < 0.001 |
| In-hospital mortality | 16 (4.95) | 4 (4.60) | 1.000 |
| 1-year mortality | 34 (10.53) | 17 (19.54) | 0.024 |
- Citation: Sun Y, Li Q, Wang H, Gu MH, Teng PK, Zhang XY, Han XD, Liu XD. Association of serum oncostatin M with disease severity and mortality in community-acquired pneumonia with diabetes mellitus. World J Diabetes 2026; 17(11): 124628
- URL: https://www.wjgnet.com/1948-9358/full/v17/i11/124628.htm
- DOI: https://dx.doi.org/10.4239/wjd.124628